![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-desktop-w27gif-57924.gif)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-mobile-w27gif-62411.gif)
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
USA (Orange Book)
Europe
0
Canada
0
Australia
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
Details:
VUMERITY (diroximel fumarate) is approved next-generation oral fumarate for treatment of adults with relapsing-remitting multiple sclerosis. Data from Phase 3 EVOLVE-MS-2 study demonstrated low discontinuation rates due to its gastrointestinal tolerability profile.
Lead Product(s): Diroximel fumarate
Therapeutic Area: Immunology Product Name: Vumerity
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 17, 2021